MUC1 and COVID-19: KL-6, which is a prognostic factor of severity in ARDS, interstitial lung disease and in COVID-19, is released by type II pneumocytes and in particular in greater quantities when there is damage to the alveolar-capillary membrane or in the process of regeneration linked to hyperplasia [74–76].